RZ-001

Phase 2Small molecule

RRznomics, Inc.

RZ-001 is one of 84 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaRecruiting

GlioblastomaRecruiting

Hepatocellular CarcinomaPhase 2

Recruiting

GlioblastomaPhase 2

Recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Novartis

Preclinical

1 2

Ibrance

Pfizer

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Hepsera

RZ-001

2 6

Coreg

Akero Therapeutics

Preclinical

2 7

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 8

Vermox

WWim Janssens

Preclinical

1 9

Valemetostat

Bristol-Myers Squibb

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Hepatocellular Carcinoma

NCT06695026

Q2 2029

Phase 1/2Active, not recruiting

Hepatocellular Carcinoma

NCT05595473

Phase 1/2Recruiting

Glioblastoma

NCT06102525

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

Recruiting·RRznomics, Inc.·Phase 1/2·NCT06695026·45 enrolled

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma

Active, not recruiting·RRznomics, Inc.·Phase 1/2·NCT05595473·42 enrolled

Glioblastoma1 trial

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma

Recruiting·RRznomics, Inc.·Phase 1/2·NCT06102525·43 enrolled

GBM1 trial

Expanded Access Program for GBM Subjects

Available·RRznomics, Inc.··NCT06676891

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for RZ-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RZ-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RZ-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rznomics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRznomics, Inc.

RZ-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2029

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Glioblastoma1 trial

GBM1 trial

References

Drug Info

Quick Facts

Related News